FDA approves two new gene therapies for sickle cell disease, a ‘functional cure’ for many patients
(NEW YORK) -- The U.S. Food and Drug Administration (FDA) on Friday announced that it has approved Casgevy, the first CRISPR gene-editing therapy for sickle cell disease, paving the way for thousands of patients in the U.S. to receive a treatment that has been... Read More.
